This open-label study randomized 92 treatment-nave patients ( 1:1 ) with advanced SCCHN into chemoradiation ( CRT nimotuzumab ) or radiation ( RT nimotuzumab ) group by investigator 's discretion ; these were further randomized into CRT + nimotuzumab or CRT and RT + nimotuzumab or RT groups , respectively .